公开(公告)号：US07579008B2

公开(公告)日：2009-08-25

申请号：US10929802

申请日：2004-08-30

Applicant: Brigitte Desiree Alberte Colau ,  Beatrice Arsene Virginie De Vos

Inventor： Brigitte Desiree Alberte Colau ,  Beatrice Arsene Virginie De Vos

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/15

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55505 ,  C12N2720/12334

Abstract: The invention provides a method of inducing an immune response against rotavirus infection from one rotavirus serotype, the method comprising administering to a subject a composition comprising an attenuated rotavirus vaccine from a different serotype. There is in particular provided a method of inducing an immune response against rotavirus infection from a non-G1 serotype, the method comprising administering to a subject a composition comprising an attenuated rotavirus vaccine from a G1 serotype.

Abstract translation: 本发明提供一种从一种轮状病毒血清型诱导针对轮状病毒感染的免疫应答的方法，所述方法包括向受试者施用包含来自不同血清型的减毒轮状病毒疫苗的组合物。 特别提供了一种从非G1血清型诱导针对轮状病毒感染的免疫应答的方法，该方法包括向受试者施用包含来自G1血清型的减毒轮状病毒疫苗的组合物。

公开(公告)号：US07560484B2

公开(公告)日：2009-07-14

申请号：US10363484

申请日：2001-08-28

Applicant: Haruki Yamada ,  Hiroaki Kiyohara ,  Takayuki Nagai ,  Toshiaki Sunazuka

Inventor： Haruki Yamada ,  Hiroaki Kiyohara ,  Takayuki Nagai ,  Toshiaki Sunazuka

IPC: A01N37/00 ,  A61K31/21

CPC classification number: A61K39/0241 ,  A61K39/0015 ,  A61K39/0016 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K39/12 ,  A61K39/145 ,  A61K39/15 ,  A61K39/39 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N2720/12334 ,  C12N2760/16134 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2770/36234 ,  Y02A50/388 ,  Y02A50/412

Abstract: The present invention provides an adjuvant that is a hydroxy unsaturated fatty acid or a derivative thereof, as well as a vaccine preparation containing the adjuvant as a constituent. For example, a vaccine shows sufficient activity to enhance the immunity when a hydroxy unsaturated fatty acid having the following structure is administered:

Abstract translation: 本发明提供了作为羟基不饱和脂肪酸或其衍生物的佐剂，以及含有佐剂作为成分的疫苗制剂。 例如，当施用具有以下结构的羟基不饱和脂肪酸时，疫苗显示出足够的活性来增强免疫力：

公开(公告)号：US07556957B2

公开(公告)日：2009-07-07

申请号：US10714534

申请日：2003-11-14

Applicant: Petrus Josephus Marie Rottier ,  Cornelis Alexander Maria De Haan ,  Bert Jan Haijema

Inventor： Petrus Josephus Marie Rottier ,  Cornelis Alexander Maria De Haan ,  Bert Jan Haijema

IPC: C12N7/04 ,  A61K39/12 ,  A61K39/215

CPC classification number: A61K39/215 ,  A61K38/00 ,  A61K39/12 ,  A61K39/225 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/552 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10034 ,  C12N2710/16334 ,  C12N2710/16734 ,  C12N2720/10034 ,  C12N2720/12234 ,  C12N2720/12334 ,  C12N2740/13034 ,  C12N2740/15034 ,  C12N2750/10034 ,  C12N2750/14334 ,  C12N2760/16134 ,  C12N2760/18134 ,  C12N2760/18434 ,  C12N2760/18534 ,  C12N2770/10034 ,  C12N2770/16034 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034 ,  C12N2770/20043 ,  C12N2770/24334 ,  C12N2770/32134 ,  C12N2800/204 ,  G01N33/56983 ,  G01N2333/165

Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. The deletion preferably results in at least a functional deletion in that the corresponding gene is not or is only partly expressed wherein the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product. One result seen with VLPs provided with deletions as provided herein is that the deleted VLP, albeit capable of replication in vitro and in vivo, are generally well attenuated, in that they do not cause disease in the target host, making them very suitable for therapeutic use, such as a delivery vehicle for genes and other cargo (wherein specific targeting may be provided as well when desired), and for use as a vaccine, being attenuated while carrying important immunogenic determinants that help elicit an immune response.

Abstract translation: 本发明涉及冠状病毒和诊断领域，治疗用途以及从其衍生的疫苗。 本发明提供复制性冠状病毒和病毒样颗粒（VLP），其基因组的大部分（至少在功能上）被删除，而不消除其复制能力。 缺失优选至少导致功能缺失，因为相应的基因不是或仅部分表达，其中所得基因产物在相应的野生型基因产物中功能失调或至少在功能上不同。 在本文提供的具有缺失的VLP所见的一个结果是缺失的VLP虽然在体外和体内都能复制，但通常是很好的减毒，因为它们不会在靶宿主中引起疾病​​，使得它们非常适合于治疗 使用，例如用于基因和其他货物的递送载体（其中当需要时可以提供特异性靶向），并用作疫苗，同时携带有助于引发免疫应答的重要的免疫原性决定簇。

公开(公告)号：US20090136545A1

公开(公告)日：2009-05-28

申请号：US11994645

申请日：2006-07-10

Applicant: Yasutaka Hoshino ,  Albert Z. Kapikian

Inventor： Yasutaka Hoshino ,  Albert Z. Kapikian

IPC: A61K39/15

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K39/15 ,  C12N2720/12334

Abstract: The present invention provides rotavirus reassortant immunogenic compositions based on a porcine rotavirus. In particular, porcine rotavirus Gottfried strain-based single VP7 or VP4 gene substitutions which can provide (i) an attenuation phenotype of a porcine rotavirus in humans and (ii) antigenic coverage for G serotypes 1, 2, 3, 4, 5, 6, 8, 9 and 10 and P serotype 1A[8], 1B[4] and 2A[6]. The compositions have been demonstrated to induce consistent levels of neutralizing antibodies against rotavirus specificities which are of global epidemiologic importance. Porcine rotavirus-based reassortant rotavirus compositions induce neutralizing antibodies against P1A[8] and P2A[6] VP4 serotypes which may provide an advantage over rhesus- or bovine-based reassortant vaccines since the VP4s of the latter vaccines do not evoke antibodies capable of neutralizing the P1A[8], or P2A[6] VP4.

Abstract translation: 本发明提供了基于猪轮状病毒的轮状病毒重配体免疫原性组合物。 特别是猪轮状病毒基于Gottfried菌株的单一VP7或VP4基因取代，其可以提供（i）人类猪轮状病毒的衰减表型和（ii）G血清型1,2,3,4,5,6的抗原性覆盖 ，8,9和10和P血清型1A [8]，1B [4]和2A [6]。 已经证明该组合物诱导具有全球流行病学重要性的轮状病毒特异性的一致的中和抗体水平。 基于猪轮状病毒的重配轮状病毒组合物诱导针对P1A [8]和P2A [6] VP4血清型的中和抗体，其可以提供优于恒河猴或牛基重配疫苗的优点，因为后者疫苗的VP4不引起能够中和的抗体 P1A [8]或P2A [6] VP4。

公开(公告)号：US07431931B2

公开(公告)日：2008-10-07

申请号：US10181908

申请日：2001-01-26

Applicant: Albert Z. Kapikian ,  Robert Chanock ,  Timo Vesikari

Inventor： Albert Z. Kapikian ,  Robert Chanock ,  Timo Vesikari

IPC: A61K39/15 ,  A61K39/12

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55 ,  C12N2720/12334

Abstract: The present invention provides compositions for making a medicament and methods for the administration of a vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human x rhesus reassortant rotavirus compositions were made which when administered during the first 7 to about 10 days of life, provided a composition which was non-reactogenic followed by booster immunizations at 16 to 18 weeks or 14 to 20 weeks, up to 1 year of age. The immune response induced by the initial neonatal administration of the live rotavirus vaccine composition protects the infant from the reactogenicity of the composition when administered as a second vaccine dose at or after 2 months of age. Administration of the immunogenic composition also is expected to ablate or significantly diminish the increase in the excess of intussusception observed 3 to 7 days following administration of the initial dose of rotavirus vaccine at about 2 to 4 months.

Abstract translation: 本发明提供了用于制备药物的组合物和用于施用用于防止人类轮状病毒病而没有显着的反应原性的疫苗组合物的方法。 制备人x恒河猴重配轮状病毒组合物，其在生命的头7至10天期间施用时，提供了在16至18周或14至20周，不超过1年的非 - 年龄。 由活轮状病毒疫苗组合物的初始新生儿施用诱导的免疫应答在2个月龄或之后作为第二种疫苗剂量施用时保护了婴儿免受组合物的反应原性。 免疫原性组合物的给药预期在约2-4个月施用初始剂量的轮状病毒疫苗后3至7天可以消融或显着减少肠套叠过量的增加。

公开(公告)号：US20080063662A1

公开(公告)日：2008-03-13

申请号：US11843815

申请日：2007-08-23

Applicant: Brigitte Colau ,  Francoise Denamur ,  Isabelle Knott ,  Annick Poliszczak ,  Georges Thiry ,  Vincent Vande Velde

Inventor： Brigitte Colau ,  Francoise Denamur ,  Isabelle Knott ,  Annick Poliszczak ,  Georges Thiry ,  Vincent Vande Velde

IPC: A61K39/00 ,  A61K35/76 ,  A61P31/00

CPC classification number: A61K39/15 ,  A61K8/0216 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/19 ,  A61K9/2095 ,  A61K39/12 ,  A61K39/39 ,  A61K47/02 ,  A61K47/183 ,  A61K47/26 ,  A61K47/36 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/55505 ,  C07K14/005 ,  C12N7/00 ,  C12N2720/12321 ,  C12N2720/12322 ,  C12N2720/12332 ,  C12N2720/12334 ,  C12N2720/12351 ,  Y02A50/466

Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

Abstract translation: 本发明提供了包含单个变体或基本上单个变体的减毒轮状病毒群，其由编码指定为VP4和VP7的主要病毒蛋白质中的至少一种的核苷酸序列限定。 本发明特别提供了称为P43的轮状病毒群体。 本发明进一步提供了一种轮状病毒疫苗的新型制剂，其是当放置在舌头上时立即溶解的快速溶解片剂形式。

公开(公告)号：US07285280B1

公开(公告)日：2007-10-23

申请号：US10049192

申请日：2000-08-15

Applicant: Brigitte Desiree Alberte Colau ,  Francoise Denamur ,  Isabelle Knott ,  Annick Poliszczak ,  Vincent Vande Velde

Inventor： Brigitte Desiree Alberte Colau ,  Francoise Denamur ,  Isabelle Knott ,  Annick Poliszczak ,  Vincent Vande Velde

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/15

CPC classification number: A61K39/15 ,  A61K8/0216 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/19 ,  A61K9/2095 ,  A61K39/12 ,  A61K39/39 ,  A61K47/02 ,  A61K47/183 ,  A61K47/26 ,  A61K47/36 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/55505 ,  C07K14/005 ,  C12N7/00 ,  C12N2720/12321 ,  C12N2720/12322 ,  C12N2720/12332 ,  C12N2720/12334 ,  C12N2720/12351 ,  Y02A50/466

Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

Abstract translation: 本发明提供了包含单个变体或基本上单个变体的减毒轮状病毒群，其由编码指定为VP4和VP7的主要病毒蛋白质中的至少一种的核苷酸序列限定。 本发明特别提供了称为P43的轮状病毒群体。 本发明进一步提供了一种轮状病毒疫苗的新型制剂，其是当放置在舌头上时立即溶解的快速溶解片剂形式。

公开(公告)号：US20070020282A1

公开(公告)日：2007-01-25

申请号：US11524192

申请日：2006-09-21

Applicant: Ulf Schroder

Inventor： Ulf Schroder

IPC: A61K39/00 ,  A61K31/23

CPC classification number: C12N7/00 ,  A61K9/0019 ,  A61K9/1274 ,  A61K39/05 ,  A61K39/12 ,  A61K39/145 ,  A61K39/15 ,  A61K39/39 ,  A61K47/12 ,  A61K47/14 ,  A61K2039/5252 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55555 ,  C12N2720/12334 ,  C12N2760/16134 ,  C12N2760/16151 ,  Y10S514/937

Abstract: A pharmaceutical formulation for parenteral or mucosal administration of antigens and/or vaccines to humans and animals, comprising monglyceride preparations having at least 80% monoglyceride content and where the acyl group contains from 6 to 24 carbon atoms, together with fatty acids where the number of carbon atoms may be varied between 4 and 22.

Abstract translation: 用于肠胃外或粘膜给予人和动物的抗原和/或疫苗的药物制剂，包括具有至少80％单酸甘油酯含量的甘油三酯制剂，其中酰基含有6至24个碳原子，以及其中数目为 碳原子可以在4和22之间变化。

公开(公告)号：US20060286109A1

公开(公告)日：2006-12-21

申请号：US11117998

申请日：2005-04-29

Applicant: Jean-Christophe Audonnet ,  Guillermo Gallo

Inventor： Jean-Christophe Audonnet ,  Guillermo Gallo

IPC: A61K39/395 ,  A61K39/116

CPC classification number: A61K35/20 ,  A61K39/002 ,  A61K39/0258 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/55 ,  A61K2039/552 ,  A61K2039/70 ,  C12N2720/12334 ,  C12N2770/20034 ,  Y02A50/474 ,  Y02A50/488

Abstract: Combination compositions including C. parvum antigen(s) or epitope(s) of interest with at least one other antigen or epitope of interest from a pathogen that causes enteric infection and/or symptoms and/or recombinant(s) and/or vector(s) and/or plasmid(s) expressing such antigen(s) or epitope(s) of interest and administration of such compositions such as to pregnant mammals and/or newborn or young mammals, for instance, pregnant cows and/or calves such as within the first month of birth, are disclosed and claimed.

Abstract translation: 组合组合物包括C.pvv抗原或目的表位与引起肠道感染和/或症状和/或重组和/或载体的病原体感兴趣的至少一种其它抗原或表位 s）和/或表达感兴趣的这种抗原或表位的质粒，并施用这样的组合物，例如怀孕哺乳动物和/或新生儿或幼年哺乳动物，例如怀孕的母牛和/或小牛，例如 在出生的第一个月内，被披露和声明。

公开(公告)号：US20060277635A1

公开(公告)日：2006-12-07

申请号：US11370697

申请日：2006-03-07

Applicant: William Langridge ,  Jie Yu ,  Takeshi Arakawa

Inventor： William Langridge ,  Jie Yu ,  Takeshi Arakawa

IPC: A61K39/116 ,  A01H1/00 ,  C12N15/82 ,  C07K14/195

CPC classification number: C12N15/8258 ,  A61K39/00 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/6037 ,  C07K14/28 ,  C07K14/62 ,  C07K2319/00 ,  C07K2319/55 ,  C12N9/88 ,  C12N15/8216 ,  C12N2720/12334 ,  Y02A50/472

Abstract: A method of inducing partial or complete immunity to an infectious disease in a mammal comprising providing to the mammal for oral consumption an effective amount of a protein complex comprising five monomeric fusion proteins.

Abstract translation: 诱导哺乳动物感染性疾病的部分或完全免疫的方法，包括向哺乳动物口服消耗有效量的包含五种单体融合蛋白的蛋白质复合物。